Search
In memoriam Daniel Catovsky
Professor Daniel Catovsky MD DSc
19. 9. 1937 – 2. 12. 2022
Daniel Catovsky died peacefully in December at the age of 85 years.
EU calls for proposal 2023
IntroductionHorizon Europe is the research and innovation programme of the EU for the period 2021-2027. The programme facilitates research collaboration and strengthens the impact of R&I in developing, supporting and implementing EU policies while tackling global challenges.
Read moreEU pilot on drug repurposing
Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.
Read more‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda
On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.
Read moreReducing bureaucracy in clinical trials: now is the time!
Medical societies and patient advocates across disciplines have joined forces with EHA to call for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper.
Read moreEvidence and policy to ensure good clinical practice
Interview with Vinay Prasad MD MPH by Heiko Becker MD, on behalf of YoungEHA
Leaders in the field that have the potential to make a difference, that challenge the way we are doing things, who push our perspective out of our…
Revising the ICH Guidelines on Clinical Trials
The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.
Read moreWithout access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
Meet Robert Hills, our August volunteer of the month
Can you tell us what you do for EHA and when you started?
I’m a relatively recent volunteer for EHA, as I only started working with them on their Clinical Research Training in Hematology (CRTH) program in 2016.
Meet Robert Hills, our August volunteer of the month
Can you tell us what you do for EHA and when you started?
I’m a relatively recent volunteer for EHA, as I only started working with them on their Clinical Research Training in Hematology (CRTH) program in 2016.